[HTML] from nih.gov…, J Cortés, L Prudkin, C Aura… - Proceedings of the …, 2011 - National Acad Sciences Clinical benefits from trastuzumab and other anti-HER2 therapies in patients with HER2 amplified breast cancer remain limited by primary or acquired resistance. To identify potential mechanisms of resistance, we established trastuzumab-resistant HER2 amplified breast cancer cells ... Cited by 5 - Related articles - All 7 versions
CM Brown, M Ray, AA Eroy-Reveles, P Egea… - Chemistry & Biology, 2011 - Elsevier The ability to follow enzyme activity in a cellular context represents a challenging technological frontier that impacts fields ranging from disease pathogenesis to epigenetics. Activity-based probes (ABPs) label the active form of an enzyme via covalent modification of catalytic residues. ... All 2 versions
N Romo, M Fitó, M Gumá, J Sala… - … and Vascular Biology, 2011 - Am Heart Assoc Objective—The contribution of human cytomegalovirus (HCMV) to vascular disease may depend on features of the immune response not reflected by the detection of specific antibodies. Persistent HCMV infection in healthy blood donors has been associated with changes in the ...
A Carreira… - Proceedings of the …, 2011 - National Acad Sciences The human tumor suppressor protein BRCA2 plays a key role in recombinational DNA repair. BRCA2 recruits RAD51 to sites of DNA damage through interaction with eight conserved motifs of approximately 35 amino acids, the BRC repeats; however, the specific function ... Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
